Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in recurrent or metastatic nasopharyngeal carcinoma
NCT03213587Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03213587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213587.